Physician profile
Daniel V Piazza
NPI 1427042431
$743.53
in general payments reported to CMS, 2019-2025
12 companies · $57.39 in 2025
The $57.39 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.72 · 2022: $193 · 2023: $197 · 2024: $248 · 2025: $57.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.31 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $368.95 | 2021-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Glaxosmithkline, LLC. | $125.28 | 2022-2024 | Arexvy |
| Esperion Therapeutics, INC. | $41.48 | 2022-2023 | Nexletol |
| Inspire Medical Systems, INC. | $36.38 | 2025 | Inspire |
| Lilly USA, LLC | $31.69 | 2022-2023 | Zepbound, Jardiance |
| Astellas Pharma US INC | $28.18 | 2023-2024 | Veozah |
| Dexcom, INC. | $24.14 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $21.17 | 2024 | Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.65 | 2023 | |
| Abbvie INC. | $16.08 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.59 | 2023 | Rexulti |
| Gilead Sciences, INC. | $13.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Piazza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.